APDS2 (Activated PI3K Delta Syndrome Type 2): A Patient Guide
At a Glance
APDS2 is a rare PIK3R1-related immune disorder that can cause repeated infections while immune activity stays too high. Care focuses on replacing missing antibodies, using targeted medicines, and monitoring swollen lymph nodes and an enlarged spleen, autoimmune problems, and long-term lung damage.
APDS2, also known as PASLI-R1, is a rare genetic condition that fundamentally changes how the immune system responds to the world. It is caused by a specific error in the PIK3R1 gene, which provides instructions for a protein that normally acts as a regulator or “brake” for immune cell activity [1]. When this gene is altered, the immune system loses its ability to regulate itself correctly, leading to a state where certain pathways are constantly stuck in the “on” position [2]. This hyperactivity creates a unique medical paradox: the immune system is simultaneously overactive and underactive, leaving the body vulnerable to infections while also causing it to over-react in ways that can lead to internal swelling or inflammation [3].
The behavior of APDS2 is characterized by several core features that require careful, lifelong management. Because the immune system’s “on-switch” is hyperactive, white blood cells often mature too quickly and fail to become effective “soldiers” against germs, resulting in frequent and recurrent infections of the ears, sinuses, and lungs [4]. At the same time, this constant signaling causes immune cells to accumulate in the lymph nodes, spleen, and digestive tract, leading to persistent swelling (lymphoproliferation) and occasionally causing the immune system to mistakenly attack the body’s own healthy tissues (autoimmunity) [5][6]. While these symptoms can be challenging, the fact that APDS2 is now understood at a molecular level means that care involves a targeted effort to manage the immune system’s specific dysfunction, though it remains a condition with variable clinical severity [7].
Living with APDS2 effectively means focusing on a few critical priorities: protecting the lungs from long-term damage (bronchiectasis), monitoring the growth of lymphoid tissue, and utilizing treatments that address the specific manifestations of the disease. Modern medicine offers a range of options, from foundational therapies that replace missing antibodies to newer, targeted medications designed to specifically “dial down” the hyperactive pathway caused by the PIK3R1 variant [8]. It is important to note that these treatments modulate the dysregulated signaling or replace antibodies, but they do not correct the gene itself. Because the condition affects every person differently—even within the same family (variable expressivity)—care must be highly individualized and coordinated by a team of specialists who understand the complexity of this rare disorder [9][10].
While a diagnosis of APDS2 brings significant new information to process, it also brings a roadmap for the future. You are moving away from a period of unexplained illness and into a phase of proactive, informed management. By working closely with a multidisciplinary care team and remaining vigilant through regular monitoring, families can manage the risks of the condition. The discovery of the genetic cause of APDS2 has opened doors to therapies that provide a path toward better-targeted care [11][12].
In this guide
6 chapters
Understanding Your APDS2 Diagnosis
Learn what an APDS2 diagnosis means, including PIK3R1 genetic testing, inheritance, diagnostic delays, family screening, and planning specialized immune care.
Recognizing the Symptoms of APDS2
Learn to recognize APDS2 symptoms including recurrent infections, swollen lymph nodes, an enlarged spleen, growth problems, digestive issues, and autoimmunity.
The Path to a Confirmed Diagnosis
Learn how APDS2 is confirmed through PIK3R1 genetic testing, immunoglobulin levels, flow cytometry, and tests to distinguish related conditions and guide care.
Managing and Treating APDS2
Learn how APDS2 treatment is tailored, from immunoglobulin and antibiotics to sirolimus, leniolisib, and HSCT, including monitoring, benefits, and risks.
Building Your Multidisciplinary Care Team
Learn how to build an APDS2 care team, prepare for specialist visits, organize records, and coordinate monitoring for lung, blood, and gut complications.
Proactive Monitoring and Red Flags
Learn how APDS2 monitoring tracks lung disease and lymphoma risk, which symptoms are red flags, and when fever, breathing problems, or bleeding need urgent care.
Common questions in this guide
What is APDS2 and what causes it?
What symptoms and health problems can APDS2 cause?
How is APDS2 diagnosed, and why does genetic testing matter?
What treatments are used for APDS2?
Why is lung monitoring important for people with APDS2?
Can APDS2 affect people differently?
Get notified when new evidence is published on immunodeficiency 132b.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.
IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ
Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.
PMID: 39679264 - 2
Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Dornan GL, Siempelkamp BD, Jenkins ML, et al.
Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.
PMID: 28167755 - 3
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134 - 4
CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.
Cura Daball P, Ventura Ferreira MS, Ammann S, et al.
Immunology and cell biology 2018; (96(10)):1060-1071 doi:10.1111/imcb.12169.
PMID: 29790605 - 5
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784 - 6
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.
Conti F, Catelli A, Cifaldi C, et al.
Frontiers in pediatrics 2021; (9()):702546 doi:10.3389/fped.2021.702546.
PMID: 34307262 - 7
Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T, Okada S, Tsumura M, et al.
Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.
PMID: 29675019 - 8
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK, Webster S, Šedivá A, et al.
Blood 2023; (141(9)):971-983 doi:10.1182/blood.2022018546.
PMID: 36399712 - 9
Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.
Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.
Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.
PMID: 35789397 - 10
Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).
Neth O, Alsina L, Rivière JG, et al.
Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.
PMID: 40028901 - 11
Leniolisib: First Approval.
Duggan S, Al-Salama ZT
Drugs 2023; (83(10)):943-948 doi:10.1007/s40265-023-01895-4.
PMID: 37256490 - 12
Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety.
Rao VK, Šedivá A, Dalm VASH, et al.
Journal of human immunity 2027; (3(1)) doi:10.70962/jhi.20260040.
PMID: 42873197
This APDS2 guide is for informational purposes and does not constitute medical advice. An immunologist and other members of your care team can interpret your PIK3R1 result and recommend monitoring and treatment for your situation.